
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934

For the month of March 2018

Commission File Number 333-168496

OSSEN INNOVATION CO., LTD.

(Translation of registrant's name into English)

518 SHANGCHENG ROAD, FLOOR 17, SHANGHAI, 200120,
PEOPLE'S REPUBLIC OF CHINA
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _____.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

OSSEN INNOVATION CO., LTD.
(Registrant)

Date: March 9, 2018

By: /s/ Wei Hua
Name: Wei Hua
Title: Chief Executive Officer

EXHIBIT INDEX

<u>Exhibit Number</u>	<u>Description</u>
99.1	Unaudited consolidated balance sheets of America-Asia Diabetes Research Foundation and Subsidiaries

AMERICA-ASIA DIABETES RESEARCH FOUNDATION AND SUBSIDIARIES

UNAUDITED CONSOLIDATED BALANCE SHEETS

ASSETS

	December 31 2017	December 31 2016	December 31, 2015
CURRENT ASSETS			
Cash and cash equivalents	\$ 138,431	\$ 325,406	\$ 2,792,374
Short-term investment - time deposits	-	-	81,444
Accounts receivable, net	139,605	132,988	1,167
Accounts receivables - related parties	345,183	586,196	-
Other receivables, net	189,124	208,636	39,927
Other receivables - related party	-	-	318,493
Inventories, net	192,128	155,590	295,211
Advance to vendors	42,484	117,181	256,329
Prepaid and other current assets	1,060	21,115	89,627
TOTAL CURRENT ASSETS	<u>1,048,015</u>	<u>1,547,112</u>	<u>3,874,572</u>
PROPERTY AND EQUIPMENT, NET PROPERTY AND EQUIPMENT, NET	<u>247,053</u>	<u>315,110</u>	<u>558,741</u>
OTHER ASSETS			
Intangible assets, net	7,859,376	8,606,942	39,936
Investment in unconsolidated subsidiary, net at cost	-	-	46,230
Deposits	21,733	26,920	127,045
TOTAL OTHER ASSETS	<u>7,881,109</u>	<u>8,633,862</u>	<u>213,211</u>
TOTAL ASSETS	<u>\$ 9,176,176</u>	<u>\$ 10,496,084</u>	<u>\$ 4,646,524</u>
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIENCY)			
CURRENT LIABILITIES			
Short term loan - bank	\$ -	\$ 575,972	\$ 770,500
Short term loans - other	-	4,319,790	4,623,000
Accounts payable	9,996	28,330	13,598
Other payables and accrued liabilities	1,348,278	4,904,854	546,393
Other payables - related parties	352,502	4,429,354	397,316
Customer deposits	559,946	635,455	2,246,066
Investment payable	-	18,888,317	19,755,188
TOTAL CURRENT LIABILITIES	<u>2,270,722</u>	<u>33,782,072</u>	<u>28,352,061</u>
OTHER LIABILITIES			
Deferred rent liabilities	-	-	129,413
TOTAL LIABILITIES	<u>2,270,722</u>	<u>33,782,072</u>	<u>28,481,474</u>
COMMITMENTS AND CONTINGENCIES			
SHAREHOLDERS' EQUITY (DEFICIENCY)			
Common stock, \$1.00 par value, 1,000,000 shares authorized, 29,976, 14,078, and 10,000 shares issued and outstanding as of December 31, 2017, 2016 and 2015, respectively	29,976	14,078	10,000
Additional paid-in-capital	41,436,177	4,364,510	-
Statutory reserves	-	-	-
Accumulated deficit	(36,694,241)	(31,352,404)	(26,038,243)
Accumulated other comprehensive income	3,057,609	4,223,834	2,616,499
TOTAL AMERICA-ASIA DIABETES RESEARCH FOUNDATION EQUITY (DEFICIENCY)	<u>7,829,521</u>	<u>(22,749,982)</u>	<u>(23,411,744)</u>
NONCONTROLLING INTEREST	<u>(924,067)</u>	<u>(536,006)</u>	<u>(423,206)</u>
TOTAL SHAREHOLDERS' EQUITY (DEFICIENCY)	<u>6,905,454</u>	<u>(23,285,988)</u>	<u>(23,834,950)</u>
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIENCY)	<u>\$ 9,176,176</u>	<u>\$ 10,496,084</u>	<u>\$ 4,646,524</u>